aztreonam has been researched along with Health Care Associated Infection in 57 studies
Aztreonam: A monocyclic beta-lactam antibiotic originally isolated from Chromobacterium violaceum. It is resistant to beta-lactamases and is used in gram-negative infections, especially of the meninges, bladder, and kidneys. It may cause a superinfection with gram-positive organisms.
aztreonam : A synthetic monocyclic beta-lactam antibiotic (monobactam), used primarily to treat infections caused by Gram-negative bacteria. It inhibits mucopeptide synthesis in the bacterial cell wall, thereby blocking peptidoglycan crosslinking.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia." | 9.09 | Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. ( Cammarata, S; Oliphant, T; Rubinstein, E; Wunderink, R, 2001) |
| "The combination aztreonam + cefotaxime (AZ + CE) was compared to amikacin + cefotaxime (AM + CE) in the treatment of nosocomial pneumonia acquired at the intensive-care unit." | 9.06 | Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime. ( Agusti Vidal, A; Almela, M; de Celis, R; Deulofeu, R; Marco, F; Rabinad, E; Rodriguez-Roisin, R; Torres, A, 1989) |
| "A multicenter trial involving several urologic units in Italy provided pooled data on 1,427 patients with urinary tract infections to evaluate the efficacy and safety of aztreonam, a new monobactam antibiotic." | 9.06 | Aztreonam in the treatment of urinary tract infections: a multicenter trial. ( Cortecchia, V; Martelli, A; Ventriglia, L, 1989) |
| "The minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were determined against 400 isolates from urological in-patients with complicated and/or hospital acquired urinary tract infections (UTI)." | 9.06 | Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections. ( Dette, GA; Grobecker, H; Kees, F; Knothe, H; Naber, KG, 1986) |
| "During the course of one year, 47 critical care patients with gram-negative bacillary pneumonia at Millard Fillmore Hospital were randomly assigned to aztreonam or tobramycin therapy (two to one)." | 9.05 | Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. ( Schentag, JJ; Simons, GW; Smith, IL; Swanson, DJ; Vari, AJ; Vigano, A; Winslade, NE, 1985) |
| "Nineteen patients with community- or hospital-acquired gram-negative pneumonia were treated with aztreonam." | 7.67 | Aztreonam therapy for gram-negative pneumonia. ( Bollinger, M; Greenberg, RN; Luppen, KL; McMillian, R; Reilly, PM, 1985) |
| "Gram-negative pneumonia is a frequent complication in hospitalized patients, particularly in those with diminished defenses." | 6.66 | Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an aminoglycoside. Spanish Study Group. ( Gobernado, M; Marco, V; Rabinad, E; Santos, M, 1989) |
| " This multinational, randomized, double-blind, controlled trial compared the efficacy, safety, and tolerability of linezolid with vancomycin in the treatment of nosocomial pneumonia." | 5.09 | Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. ( Cammarata, S; Oliphant, T; Rubinstein, E; Wunderink, R, 2001) |
| "The combination aztreonam + cefotaxime (AZ + CE) was compared to amikacin + cefotaxime (AM + CE) in the treatment of nosocomial pneumonia acquired at the intensive-care unit." | 5.06 | Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime. ( Agusti Vidal, A; Almela, M; de Celis, R; Deulofeu, R; Marco, F; Rabinad, E; Rodriguez-Roisin, R; Torres, A, 1989) |
| "A multicenter trial involving several urologic units in Italy provided pooled data on 1,427 patients with urinary tract infections to evaluate the efficacy and safety of aztreonam, a new monobactam antibiotic." | 5.06 | Aztreonam in the treatment of urinary tract infections: a multicenter trial. ( Cortecchia, V; Martelli, A; Ventriglia, L, 1989) |
| "The minimal inhibitory concentrations (MICs) of aztreonam and cefotaxime were determined against 400 isolates from urological in-patients with complicated and/or hospital acquired urinary tract infections (UTI)." | 5.06 | Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections. ( Dette, GA; Grobecker, H; Kees, F; Knothe, H; Naber, KG, 1986) |
| "During the course of one year, 47 critical care patients with gram-negative bacillary pneumonia at Millard Fillmore Hospital were randomly assigned to aztreonam or tobramycin therapy (two to one)." | 5.05 | Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia. ( Schentag, JJ; Simons, GW; Smith, IL; Swanson, DJ; Vari, AJ; Vigano, A; Winslade, NE, 1985) |
| "Nineteen patients with community- or hospital-acquired gram-negative pneumonia were treated with aztreonam." | 3.67 | Aztreonam therapy for gram-negative pneumonia. ( Bollinger, M; Greenberg, RN; Luppen, KL; McMillian, R; Reilly, PM, 1985) |
| " An adequate standard dosage of aztreonam could be established as 3-4 g/day in compromised patients, and it should be combined with gram-positive coverage when used empirically." | 2.66 | A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients. ( Bosch-Perez, A; Rabinad, E, 1989) |
| "Gram-negative pneumonia is a frequent complication in hospitalized patients, particularly in those with diminished defenses." | 2.66 | Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an aminoglycoside. Spanish Study Group. ( Gobernado, M; Marco, V; Rabinad, E; Santos, M, 1989) |
| "Aztreonam has undoubtedly high clinical and bacteriological efficacy in the therapy of nosocomial infections in patients with impaired host defenses." | 2.66 | Aztreonam in the therapy of nosocomial infections in patients with impaired host defenses. ( Cristiano, P; Iovene, MR; Paradisi, F, 1985) |
| "Aztreonam has a high affinity for the protein-binding protein 3 (PBP-3) of aerobic gram-negative bacteria." | 2.38 | How and why aztreonam works. ( Rittenbury, MS, 1990) |
| "Pseudomonas aeruginosa is related to nosocomial infections, and it tends to become resistant during or after antimicrobial treatment." | 1.51 | In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa. ( Li, J; Ma, W; Sun, S; Wang, D; Yu, C, 2019) |
| "A total of 143 patients with nosocomial infections due to K." | 1.33 | Nosocomial infection with cephalosporin-resistant Klebsiella pneumoniae is not associated with increased mortality. ( Gomes, CC; Levin, AS; Santos, CR; Vormittag, E, 2006) |
| "Tigemonam proved to be a bactericidal antibiotic." | 1.28 | In vitro activity of tigemonam against multiresistant nosocomial Enterobacteriaceae. ( Avlamis, A; Giamarellou, H; Grammatikou, M; Papoulias, G; Pephanis, A, 1989) |
| "Aztreonam was administered as a single therapy to 7 patients and in association with metronidazole (18) and/or penicillin G (14) to 22 patients; in fact, anaerobes were isolated in ten patients." | 1.27 | [Aztreonam treatment of severe infections caused by gram-negative aerobic bacilli]. ( Dupeyron, JP; Froehly, S; Jehl, F; Monteil, H; Peter, JD; Rosset, MA, 1988) |
| "So carumonam was at the second place from eight tested products, after latamoxef (97." | 1.27 | [Comparative antibacterial activity of a new monobactam, carumonam (RO 17-2301, AMA 1080) on hospital bacteria resistant to beta lactams]. ( Croize, J; Le Noc, D; Le Noc, P, 1987) |
| "Aztreonam has shown the highest activity against all the tested strains, with a geometrical mean of MICs (MG) of 0." | 1.27 | [Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals]. ( Amato, G; Anzivino, D; Bolletti-Censi, M; Covelli, I; Fortunato, A; Guarino, A; Gulletta, E; Lavitola, A; Nani, E; Spagnoletti, G, 1986) |
| "Aztreonam is a novel antimicrobial agent belonging to the monobactam class of antibiotics." | 1.27 | Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa. ( Neu, HC; Scully, BE, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (54.39) | 18.7374 |
| 1990's | 9 (15.79) | 18.2507 |
| 2000's | 12 (21.05) | 29.6817 |
| 2010's | 4 (7.02) | 24.3611 |
| 2020's | 1 (1.75) | 2.80 |
| Authors | Studies |
|---|---|
| Paul, D | 1 |
| Chanda, DD | 1 |
| Chakravarty, A | 1 |
| Bhattacharjee, A | 1 |
| Shaw, E | 1 |
| Rombauts, A | 1 |
| Tubau, F | 1 |
| Padullés, A | 1 |
| Càmara, J | 1 |
| Lozano, T | 1 |
| Cobo-Sacristán, S | 1 |
| Sabe, N | 1 |
| Grau, I | 1 |
| Rigo-Bonnin, R | 1 |
| Dominguez, MA | 1 |
| Carratalà, J | 1 |
| Ma, W | 1 |
| Li, J | 1 |
| Wang, D | 1 |
| Yu, C | 1 |
| Sun, S | 1 |
| Dupont, H | 1 |
| Marciniak, S | 1 |
| Zogheib, E | 1 |
| Mammeri, H | 1 |
| Friggeri, A | 1 |
| Ammenouche, N | 1 |
| Levrard, M | 1 |
| Airapetian, N | 1 |
| Tinturier, F | 1 |
| Mahjoub, Y | 1 |
| Marcano, D | 1 |
| Pasterán, F | 1 |
| Rapoport, M | 1 |
| Faccone, D | 1 |
| Ugarte, C | 1 |
| Salgado, N | 1 |
| Payares, D | 1 |
| Spadola, E | 1 |
| López, Y | 1 |
| Maggi, G | 1 |
| Galas, M | 1 |
| Sánchez, D | 1 |
| Piekarska, K | 1 |
| Zacharczuk, K | 1 |
| Szych, J | 1 |
| Zawidzka, E | 1 |
| Wilk, E | 1 |
| Wardak, S | 1 |
| Jagielski, M | 1 |
| Gierczyński, R | 1 |
| Wunderink, RG | 1 |
| Cammarata, SK | 1 |
| Oliphant, TH | 1 |
| Kollef, MH | 1 |
| Gomes, CC | 1 |
| Vormittag, E | 1 |
| Santos, CR | 1 |
| Levin, AS | 1 |
| Parkins, MD | 1 |
| Pitout, JDD | 1 |
| Church, DL | 1 |
| Conly, JM | 1 |
| Laupland, KB | 1 |
| Gospodarek, E | 1 |
| Gierlotka, K | 1 |
| Deptuła, A | 1 |
| Michalska, A | 1 |
| Joly-Guillou, ML | 1 |
| Serieys, C | 1 |
| Verin-Prevost, C | 1 |
| Bergogne-Berezin, E | 1 |
| Henahan, J | 1 |
| Just, HM | 1 |
| Phillips, E | 1 |
| Bassler, M | 1 |
| Daschner, FD | 1 |
| Zemelman, R | 1 |
| Bello, H | 1 |
| Dominguez, M | 1 |
| Gonzalez, G | 1 |
| Mella, S | 1 |
| Garcia, A | 1 |
| Babálová, M | 2 |
| Blahová, J | 1 |
| Lesická-Hupková, M | 1 |
| Krcméry, V | 3 |
| Kubonová, K | 2 |
| Krălíková, K | 1 |
| Polk, HC | 1 |
| Livingston, DH | 1 |
| Fry, DE | 1 |
| Malangoni, MA | 1 |
| Fabian, T | 1 |
| Trachtenberg, LS | 1 |
| Gardner, SA | 1 |
| Kesterson, L | 1 |
| Cheadle, WG | 1 |
| Gilad, J | 1 |
| Borer, A | 1 |
| Peled, N | 1 |
| Riesenberg, K | 1 |
| Tager, S | 1 |
| Appelbaum, A | 1 |
| Schlaeffer, F | 1 |
| Shehabi, AA | 1 |
| Mahafzah, A | 1 |
| Baadran, I | 1 |
| Qadar, FA | 1 |
| Dajani, N | 1 |
| Boucher, BA | 1 |
| Nadjar, D | 1 |
| Rouveau, M | 1 |
| Verdet, C | 1 |
| Donay, L | 1 |
| Herrmann, J | 1 |
| Lagrange, PH | 1 |
| Philippon, A | 1 |
| Arlet, G | 1 |
| Rubinstein, E | 1 |
| Cammarata, S | 1 |
| Oliphant, T | 1 |
| Wunderink, R | 1 |
| Raad, I | 1 |
| Hachem, R | 1 |
| Hanna, H | 1 |
| Abi-Said, D | 1 |
| Bivins, C | 1 |
| Walsh, G | 1 |
| Thornby, J | 1 |
| Whimbey, E | 1 |
| Huaringa, A | 1 |
| Sukumaran, A | 1 |
| Jeong, SH | 1 |
| Kim, WM | 1 |
| Chang, CL | 1 |
| Kim, JM | 1 |
| Lee, K | 1 |
| Chong, Y | 1 |
| Hwang, HY | 1 |
| Baek, YW | 1 |
| Chung, HK | 1 |
| Woo, IG | 1 |
| Ku, JY | 1 |
| Fayed, DF | 1 |
| Dahmash, NS | 1 |
| Saddique, AA | 1 |
| Shibl, AM | 2 |
| Gomez-Alferez, A | 1 |
| Baquero, F | 1 |
| Canton, R | 1 |
| Loza, E | 1 |
| Martinez-Beltran, J | 1 |
| Rittenbury, MS | 1 |
| Nichols, RL | 1 |
| Cook, JL | 2 |
| Seginková, Z | 1 |
| Antal, M | 1 |
| Knothe, H | 2 |
| Rabinad, E | 4 |
| Bosch-Perez, A | 1 |
| Torres, A | 1 |
| de Celis, R | 1 |
| Marco, F | 1 |
| Almela, M | 1 |
| Deulofeu, R | 1 |
| Rodriguez-Roisin, R | 1 |
| Agusti Vidal, A | 1 |
| Birolini, D | 1 |
| Moraes, MF | 1 |
| de Souza, OS | 1 |
| Ishag, AH | 1 |
| Durgham, SM | 1 |
| Martelli, A | 1 |
| Cortecchia, V | 1 |
| Ventriglia, L | 1 |
| Rivera-Vazquez, CR | 1 |
| Ramirez-Ronda, CH | 1 |
| Rodriguez, JR | 1 |
| Saavedra, S | 1 |
| Marco, V | 1 |
| Gobernado, M | 1 |
| Santos, M | 1 |
| Giamarellou, H | 1 |
| Pephanis, A | 1 |
| Grammatikou, M | 1 |
| Avlamis, A | 1 |
| Papoulias, G | 1 |
| Peter, JD | 1 |
| Jehl, F | 1 |
| Froehly, S | 1 |
| Dupeyron, JP | 1 |
| Monteil, H | 1 |
| Rosset, MA | 1 |
| Roberts, JA | 1 |
| Le Noc, P | 1 |
| Croize, J | 1 |
| Le Noc, D | 1 |
| Pomeroy, L | 1 |
| Noone, P | 1 |
| Roselle, GA | 1 |
| Crotti, D | 1 |
| Barbieri, C | 1 |
| Cellie, P | 1 |
| Fonzo, G | 1 |
| Visintin, F | 1 |
| Nikolaidis, P | 1 |
| Alexiou, P | 1 |
| Tourkantonis, A | 1 |
| Covelli, I | 1 |
| Bolletti-Censi, M | 1 |
| Fortunato, A | 1 |
| Guarino, A | 1 |
| Spagnoletti, G | 1 |
| Amato, G | 1 |
| Nani, E | 1 |
| Anzivino, D | 1 |
| Lavitola, A | 1 |
| Gulletta, E | 1 |
| Soussy, CJ | 1 |
| Le Van Thoi, J | 1 |
| Duval, JR | 1 |
| García-Rodríguez, JA | 1 |
| Naber, KG | 1 |
| Dette, GA | 1 |
| Kees, F | 1 |
| Grobecker, H | 1 |
| Schentag, JJ | 1 |
| Vari, AJ | 1 |
| Winslade, NE | 1 |
| Swanson, DJ | 1 |
| Smith, IL | 1 |
| Simons, GW | 1 |
| Vigano, A | 1 |
| Childs, SJ | 1 |
| Starr, SE | 1 |
| Cristiano, P | 1 |
| Iovene, MR | 1 |
| Paradisi, F | 1 |
| Greenberg, RN | 1 |
| Reilly, PM | 1 |
| Luppen, KL | 1 |
| Bollinger, M | 1 |
| McMillian, R | 1 |
| Scully, BE | 1 |
| Neu, HC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Linezolid Alone or Combined With Carbapenem Against Methicillin-resistant Staphylococcus Aureus (MRSA) in Vitro and in Ventilator-associated Pneumonia[NCT01356472] | Phase 4 | 60 participants (Anticipated) | Interventional | 2011-06-30 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for aztreonam and Health Care Associated Infection
| Article | Year |
|---|---|
Hospital-acquired brevundimonas vesicularis septicaemia following open-heart surgery: case report and literature review.
Topics: Adult; Anti-Infective Agents; Aztreonam; Ciprofloxacin; Cross Infection; Female; Humans; Microbial S | 2000 |
Role of aztreonam in the treatment of nosocomial pneumonia in the critically ill surgical patient.
Topics: Aztreonam; Cost-Benefit Analysis; Critical Illness; Cross Infection; Drug Costs; Humans; Monobactams | 2000 |
How and why aztreonam works.
Topics: Aztreonam; Cross Infection; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Postoperati | 1990 |
Role of aztreonam in lower respiratory tract infections.
Topics: Aztreonam; Bacterial Infections; Cross Infection; Drug Evaluation; Gram-Negative Bacteria; Humans; I | 1988 |
Role of aztreonam in urinary tract infections.
Topics: Aztreonam; Bacteriuria; Clinical Trials as Topic; Cross Infection; Drug Resistance, Microbial; Human | 1988 |
Antimicrobial therapy of bacterial sepsis in the newborn infant.
Topics: Aminoglycosides; Ampicillin; Anti-Bacterial Agents; Aztreonam; Bacteria; Cephalosporins; Cross Infec | 1985 |
17 trials available for aztreonam and Health Care Associated Infection
| Article | Year |
|---|---|
Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia.
Topics: Acetamides; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents | 2003 |
Feisty gram-negative aerobes succumb to new antibiotic group.
Topics: Anti-Bacterial Agents; Aztreonam; Clinical Trials as Topic; Cross Infection; Drug Resistance, Microb | 1982 |
Treatment of pneumonia in mechanically ventilated trauma patients. Results of a prospective trial.
Topics: Aztreonam; Bronchoalveolar Lavage Fluid; Cilastatin; Cross Infection; Drug Therapy, Combination; HLA | 1997 |
Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.
Topics: Acetamides; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Cross Infection; Doubl | 2001 |
Treatment of nosocomial postoperative pneumonia in cancer patients: a prospective randomized study.
Topics: Aged; Amikacin; Aztreonam; Chi-Square Distribution; Clindamycin; Cross Infection; Drug Therapy, Comb | 2001 |
Evaluation of aztreonam in the treatment of serious gram-negative infections in a university hospital in Saudi Arabia.
Topics: Acinetobacter; Acinetobacter Infections; Adult; Aztreonam; Bacteremia; Citrobacter; Cross Infection; | 1992 |
A multicenter comparative trial of aztreonam in the treatment of gram-negative infections in compromised intensive-care patients.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacterial Infecti | 1989 |
Therapeutic efficacy of the combination of aztreonam with cefotaxime in the treatment of severe nosocomial pneumonia. Comparative study against amikacin combined with cefotaxime.
Topics: Adult; Aged; Amikacin; Aztreonam; Cefotaxime; Clinical Trials as Topic; Cross Infection; Drug Therap | 1989 |
Comparison of aztreonam plus clindamycin with tobramycin plus clindamycin in the treatment of intra-abdominal infections.
Topics: Abdomen; Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Clindamycin; C | 1989 |
Aztreonam in the treatment of urinary tract infections: a multicenter trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Child; Cross Infection; | 1989 |
A comparative analysis of aztreonam + clindamycin versus tobramycin + clindamycin or amikacin + mezlocillin in the treatment of gram-negative lower respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Amikacin; Aztreonam; Bacterial Infections; Clindamycin; Clinical Tri | 1989 |
Comparative study of aztreonam in gram-negative pneumonia versus a therapeutic regimen that includes an aminoglycoside. Spanish Study Group.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacterial Infecti | 1989 |
Role of aztreonam in urinary tract infections.
Topics: Aztreonam; Bacteriuria; Clinical Trials as Topic; Cross Infection; Drug Resistance, Microbial; Human | 1988 |
Pharmacokinetics, in-vitro activity, therapeutic efficacy and clinical safety of aztreonam vs. cefotaxime in the treatment of complicated urinary tract infections.
Topics: Adult; Aged; Aztreonam; Cefotaxime; Cross Infection; Female; Gram-Negative Bacteria; Gram-Positive B | 1986 |
Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Clinical Trials as Topic; Critical Car | 1985 |
Aztreonam in the treatment of urinary tract infection.
Topics: Anti-Bacterial Agents; Aztreonam; Cefamandole; Cross Infection; Drug Resistance, Microbial; Escheric | 1985 |
Aztreonam in the therapy of nosocomial infections in patients with impaired host defenses.
Topics: Adult; Aged; Anti-Bacterial Agents; Aztreonam; Clinical Trials as Topic; Cross Infection; Female; Hu | 1985 |
35 other studies available for aztreonam and Health Care Associated Infection
| Article | Year |
|---|---|
An insight into analysis and elimination of plasmids encoding metallo-β-lactamases in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Cefotaxime; Cross Infection; DNA Copy Number Vari | 2020 |
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Aztreonam; beta-Lactam Resista | 2018 |
In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefoperazone; Ceftazidime; China; Cross Infection; Dr | 2019 |
Use of aztreonam in association with cefepime for the treatment of nosocomial infections due to multidrug-resistant strains of Pseudomonas aeruginosa to β-lactams in ICU patients: A pilot study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aztreonam; Bacterial Proteins; beta-Lactam Re | 2015 |
First isolation of a VIM-producing Klebsiella pneumoniae from a seven-year-old child in Venezuela.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; beta-Lactamases; Cefepime; Cephalosporins; | 2008 |
[Dissemination of the KPC carbapenemase producing Klebsiella pneumoniae in a hospital in Warsaw, Poland].
Topics: Adult; Aged; Aztreonam; Bacterial Proteins; beta-Lactamases; Cefotaxime; Ceftazidime; Ciprofloxacin; | 2010 |
Nosocomial infection with cephalosporin-resistant Klebsiella pneumoniae is not associated with increased mortality.
Topics: Aztreonam; Brazil; Cephalosporin Resistance; Cross Infection; Drug Resistance, Bacterial; Female; Hu | 2006 |
Treatment of infections caused by metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Calgary Health Region.
Topics: Aged; Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Canada; Catchment Area, Health; Colistin; C | 2007 |
[Imipenem resistance in Gram-negative rods and its consumption between 1999 and 2005].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactam Resistance; Carbapenems; Colistin; Cross Infection; Dr | 2007 |
[Comparative in vitro activity of 6 recent beta-lactams against hospital strains of Acinetobacter calcoaceticus: role of the monobactam SQ 26,776].
Topics: Acinetobacter; Acinetobacter Infections; Anti-Bacterial Agents; Aztreonam; Cross Infection; Drug Res | 1983 |
Combination effect of azthreonam with four aminoglycosides on nosocomial gram-positive cocci and non-fermenting gram-negative bacteria.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacteria; Cross Infection; Drug Synergism; Fermen | 1982 |
Activity of imipenem, third-generation cephalosporins, aztreonam and ciprofloxacin against multi-resistant gram-negative bacilli isolated from Chilean hospitals.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Chile; Ciprofloxacin; Cross Infection; Drug Resist | 1993 |
Transfer of ceftazidime and aztreonam resistance from nosocomial strains of Xanthomonas (Stenotrophomonas) maltophilia to a recipient strain of Pseudomonas aeruginosa ML-1008.
Topics: Anti-Bacterial Agents; Aztreonam; Ceftazidime; Conjugation, Genetic; Cross Infection; Drug Resistanc | 1995 |
[Variation in transfer resistance to cefotaxime, ceftazidime and aztreonam in strains of Acinetobacter sp., Enterobacter sp. and Citrobacter sp. isolated from the same university hospitals].
Topics: Acinetobacter; Aztreonam; Cefotaxime; Ceftazidime; Cephalosporins; Citrobacter; Cross Infection; Dru | 1996 |
High incidence of Klebsiella pneumoniae clinical isolates to extended-spectrum B-lactam drugs in intensive care units.
Topics: Aztreonam; beta-Lactam Resistance; Cefotaxime; Ceftazidime; Ceftriaxone; Cross Infection; Gram-Negat | 2000 |
Outbreak of Klebsiella pneumoniae producing transferable AmpC-type beta-lactamase (ACC-1) originating from Hafnia alvei.
Topics: Amino Acid Sequence; Aztreonam; Bacterial Proteins; Base Sequence; beta-Lactamases; Cefepime; Cefota | 2000 |
Neonatal intensive care unit outbreak caused by a strain of Klebsiella oxytoca resistant to aztreonam due to overproduction of chromosomal beta-lactamase.
Topics: Aztreonam; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Ceftriaxone; Cross Infection | 2001 |
The incidence and beta-lactam resistance of Proteus vulgaris in hospital infections: the last decade.
Topics: Ampicillin Resistance; Anti-Bacterial Agents; Aztreonam; Bacteremia; beta-Lactamases; Cephalosporins | 1991 |
Surgery-related infections: a challenge for the physician. Introduction.
Topics: Aminoglycosides; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cross Infection; Drug Resis | 1990 |
Gram-negative bacillary pneumonia in the nosocomial setting. Role of aztreonam therapy.
Topics: Aztreonam; Bacterial Infections; Cross Infection; Gram-Negative Bacteria; Humans; Microbial Sensitiv | 1990 |
Transductional analysis of imipenem-ceftazidime-and azactam resistant Pseudomonas aeruginosa strains from nosocomial infections.
Topics: Aztreonam; Ceftazidime; Cross Infection; Drug Resistance, Microbial; Humans; Hydrolysis; Imipenem; P | 1989 |
Comparative in vitro antibacterial activity of aztreonam against clinical isolates of gram-negative bacteria.
Topics: Aztreonam; Cefoperazone; Cefotaxime; Ceftazidime; Cross Infection; Gentamicins; Gram-Negative Bacter | 1989 |
In vitro activity of tigemonam against multiresistant nosocomial Enterobacteriaceae.
Topics: Aztreonam; Ceftriaxone; Cross Infection; Drug Resistance, Microbial; Enterobacteriaceae Infections; | 1989 |
[Aztreonam treatment of severe infections caused by gram-negative aerobic bacilli].
Topics: Aged; Aged, 80 and over; Aztreonam; Bacterial Infections; Cross Infection; Drug Evaluation; Female; | 1988 |
[Comparative antibacterial activity of a new monobactam, carumonam (RO 17-2301, AMA 1080) on hospital bacteria resistant to beta lactams].
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Cross Infection; Gram-Negative Bacteria; Humans; Mic | 1987 |
Aztreonam: its role in the treatment of nosocomial infections. Proceedings of a symposium. New Orleans, Louisiana, November 14, 1987.
Topics: Aztreonam; Cross Infection; Humans | 1988 |
Aztreonam treatment of sepsis.
Topics: Adolescent; Adult; Aged; Aztreonam; Bacterial Infections; Cross Infection; Female; Humans; Male; Mid | 1988 |
Nosocomial and nursing home-acquired pneumonia. Recent therapeutic advances.
Topics: Anti-Bacterial Agents; Aztreonam; Cephalosporins; Cilastatin; Clavulanic Acid; Clavulanic Acids; Cro | 1987 |
In vitro activity of aztreonam against Pseudomonas: epidemiological aspects.
Topics: Anti-Bacterial Agents; Aztreonam; Cross Infection; Humans; Microbial Sensitivity Tests; Pseudomonas; | 1987 |
Clinical experience with aztreonam in the treatment of nosocomial infections.
Topics: Aztreonam; Bacteria; Cross Infection; Humans; Microbial Sensitivity Tests | 1987 |
[Evaluation of the in vitro activity of aztreonam on 1990 gram-negative bacterial strains recently isolated in Campania hospitals].
Topics: Aztreonam; Cefotaxime; Ceftazidime; Cross Infection; Gentamicins; Gram-Negative Bacteria; Humans; In | 1986 |
[In vitro activity of carumonam (RO 17-2301) on hospital bacteria].
Topics: Anti-Bacterial Agents; Aztreonam; Bacteria; Cross Infection; Humans; Lactams; Microbial Sensitivity | 1986 |
[Aztreonam in severe gram-negative infections in hospitalized patients. Clinical experience in Spain. Preliminary data].
Topics: Adolescent; Adult; Aged; Aztreonam; Bacterial Infections; Cross Infection; Female; Gram-Negative Bac | 1987 |
Aztreonam therapy for gram-negative pneumonia.
Topics: Adult; Aged; Alcoholism; Anti-Bacterial Agents; Aztreonam; Bacterial Infections; Cross Infection; Dr | 1985 |
Use of aztreonam in the treatment of serious infections due to multiresistant gram-negative organisms, including Pseudomonas aeruginosa.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Arthritis, Infectious; Aztreonam; Bacterial Infectio | 1985 |